Drugs / Neoantigen-loaded DC vaccine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03871205 | Apr 2019 → Jun 2020 | non-small cell lung carcinoma, small cell lung carcinoma | Shenzhen People's Hospital | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06751849 | Mar 2024 → Mar 2026 overdue | non-small cell lung carcinoma | The First Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06752057 | Sep 2024 → Aug 2026 overdue | non-small cell lung carcinoma | The First Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
| — | NCT06751940 | Sep 2024 → Aug 2026 overdue | colorectal cancer | The First Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
| — | NCT06751953 | Sep 2024 → Aug 2026 overdue | colorectal cancer | The First Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neoantigen-loaded DC vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06751940 ↗ |
| Modality | Vaccine | “Neoantigen-loaded dendritic cell (DC) vaccines” NCT03871205 ↗ |
| Route | Subcutaneous | “DC vaccine will be injected subcutaneously” NCT03871205 ↗ |